A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder

• Time to relapse (days)
  

• Change from baseline in total PANSS and PANSS subscale scores and CGI severity score; 1-year relapse rate; QOLI (quality of life); safety evaluations conducted throughout the study
  

Schizophrenia is a severe mental illness that causes changes in a person's perception, thoughts, and behaviour. In schizophrenics, the most common symptoms are positive symptoms (delusions and hallucinations), negative symptoms (avoiding social situations, lack of feeling or expression), and disorganized symptoms (confusion in thinking and speech). Schizoaffective disorder is different from schizophrenia, although it may be misdiagnosed as this illness. Schizoaffective disorder is a mental illness distinguished by a combination of a thought disorder (abnormal thinking or psychotic symptoms such as hallucinations or delusions) and a mood disorder (clinical depression or manic component). Manic symptoms include, but are not limited to an overinflated self esteem, increased physical agitation, excessively poor judgment, being easily distracted, and an increased irritability and energy level. This is a randomized, double-blind, parallel-group, controlled study comparing the time to relapse and the incidence of relapse in patients with schizophrenia and schizoaffective disorder being treated with risperidone or haloperidol. The long-term safety and effectiveness of risperidone and haloperidol are also compared. The study is composed of two phases: a 1-week baseline period and a double-blind treatment period. During the baseline period, the doses of risperidone and haloperidol are gradually increased to 4 mg/day for risperidone and 10 mg/day for haloperidol. During the first 4 weeks of double-blind treatment, dosage adjustments can be made in the range of 2 - 8 mg/day for risperidone and 5 - 20 mg/day for haloperidol, based on clinical evaluations of the patient. The double-blind treatment continues at that dose until the last patient entering the study completes 1 year of treatment or for a maximum of 112 weeks. The primary measure of effectiveness is the time to relapse, which is defined using six criteria that indicate the patient's illness is no longer under control (for example, psychiatric hospitalization). Additional efficacy testing conducted includes the Positive and Negative Syndrome Scale for Schizophrenia (PANSS), a rating scale that measures the symptoms of schizophrenia; the Clinical Global Impressions (CGI), a rating system used to evaluate the overall and severity of clinical change in a patient with various diseases affecting the brain; and the Quality of Life Interview (QOLI), a global measure of satisfaction with life. Safety evaluations include the incidence of adverse events, results of clinical laboratory tests (hematology, biochemistry, urinalysis), measurements of vital signs and body weight, physical examination and electrocardiogram (ECG) findings, and the Extrapyramidal Symptoms Rating Scale (ESRS), a scale used to measure effects of antipsychotic medications on motor functions of the patient. The study hypothesis is that risperidone will be more effective in delaying relapse than haloperidol in patients with schizophrenia and schizoaffective disorder. Risperidone tablets, taken orally, starting at 1 mg/day; increasing to 4 mg/day (Week 1). Haloperidol tablets, taken orally, starting at 2 mg/day; increasing to 10 mg/day (Week 1). After Week 1, dosage may be adjusted (2 - 8 mg/day risperidone; 5 - 20 mg/day haloperidol). Treatment duration >=52 weeks.